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Androgen therapy in hemodialysis patients: I. Effects on red cell oxygen
transport. Measures related to red cell oxygen transport were evaluated
in 17 hemodialysis patients receiving androgen therapy, 15 untreated
hemodialysis patients and 15 normal subjects. Hemoglobin levels were
higher in androgen—treated patients than in the untreated population
and were directly related to the reticulocyte index. Hill coefficients
were normal, and in vivo P50 values were increased to the same degree
in both dialysis groups. However, DPG and serum phosphate explained
70% and 12%, respectively, of the variance in P50 in untreated patients
but only 2% and 5% in androgen—treated subjects. In contrast, sample
pH explained 34% of the variance in P50 in the androgen—treated group
and less than 1% in the untreated dialysis population. Despite the
relative importance of pH as a determinant of P50 in patients on
androgen therapy, the Bohr coefficient in this group was only about half
of that in untreated dialysis subjects. Androgen—treated patients also
had lower red cell ATP levels. Finally, the expected correlation of
MCHC with pH was noted in untreated dialysis subjects but not in
patients receiving androgens. We conclude that androgen therapy in
hemodialysis patients in addition to increasing red cell production,
directly alters red cell metabolism. Moreover, although the androgen
regimens used did not change the net oxygen transport characteristics
of hemoglobin, they decreased the responsiveness of hemoglobin—
oxygen affinity to changes in pH, DPG and phosphate. Thus, red cell
adaptation to changes in oxygen supply and/or demand may be limited
in androgen treated patients, and the improvement in clinical perform-
ance expected from androgen—stimulated erythropoiesis may not be
realized.
A variety of androgen preparations have been shown to
stimulate erythropoiesis and to increase the red cell (RBC) mass
in chronic hemodialysis (CHD) patients [1—9]. It has been
suggested that these effects result from increased erythropoietin
production; increased proliferation of erythropoietin—sensitive
stem cells; and/or increased sensitivity of stem cell populations
to erythropoietin [10—15]. Moreover, in both man and experi-
mental animals, some androgens have been shown to increase
RBC 2,3-DPG levels and decrease hemoglobin—oxygen affinity
(that is, higher P50 values) [16—18]. These changes may reflect:
1) a direct or indirect effect of androgens on RBC metabolism;
2) an increased proportion of "young" RBC in the peripheral
blood; and/or 3) an increase in systemic oxygen requirements
during androgen therapy. To evaluate these possibilities, we
have studied factors affecting hemoglobin—oxygen affinity in
CHD patients receiving androgens (A), CHD patients not on
androgen therapy (NA), and normal controls. Our results
suggest that, in addition to increasing the proportion of circu-
lating young RBC in CHD patients, androgens have effects on
RBC metabolism and on the interaction of hemoglobin with the
RBC milieu which, to our knowledge, have not been previously
reported.
Methods
All reagents were obtained from the Sigma Chemical Com-
pany (St. Louis, Missouri, USA). Blood samples from CHD
patients for all laboratory tests were obtained from peripheral
veins just prior to instituting dialysis following the longest
interdialytic period (66 hours). Serum total CO2 as bicarbonate,
serum phosphate, serum creatinine and BUN were measured
by standard clinical laboratory methods using venous blood.
Hematocrit values were obtained by the micro-hematocrit
method, hemoglobin (Hgb) was measured as cyanomethemo-
globin [19], and mean corpuscular hemoglobin concentration
(MCHC) was calculated as the ratio of Hgb to hematocrit.
Reticulocyte counts were determined by examination of 1000
red cells following supravital staining with new methylene blue
and the reticulocyte index was calculated by multiplying these
values by the ratio of the patient's hematocrit to a normal
baseline of 45 [20]. Serum ferritin was determined by Dr. J.D.
Cook using a previously described method [21]. Previous stud-
ies have shown that absent marrow iron stores are consistently
associated with serum ferritin levels below 50 ng/ml [221.
Hemoglobin-oxygen dissociation curves were generated on
freshly drawn venous blood using an Aminco Hem-0-Scan
recorder which maintains a constant pCO2 level of 40 torr and
a temperature of 37°. The partial pressure of oxygen at which
Hgb was 50% saturated with oxygen was determined directly
from the curve and designated 5OM The pH of these samples
(pHM) was calculated from the Henderson—Hasselbach equa-
tion:
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Total CO2 was determined as serum bicarbonate and pCO2 was
fixed at 40 torr. Heme—heme interaction was calculated as the
Hill coefficient [23]. Values for PSOM were corrected to pH 7.4
100
PHM = 6.1 + log
Total CO2 — 0.03CO2
0.03C02
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Table 1. Renal and hematologic characteristics of CHD patient groups
Reticulocyte
BUN Creatinine Hemoglobin MCV
mg/dl mg/dl gidi
MCHC
gidi
index
%
Normal (15) — — 14.75 1.49 89 4 34.2 1.6 —
No androgens (15) 75 27 13.3 5.1 8.56 1.40 86 8 32.5 2.1 0.9 1.1
(33 — 106) (6.2 — 25.0) (5.60 — 11.80) (69 — 102) (27.5 — 32.1) (0.1 — 4.7)
Androgens (17) 74 26 13.6 4.6 11.31 2.49 93 6 31.9 1.6 1.9 1.5
(39 — 134) (9.7 — 22.0) (7.60 — 16.90) (83 — 106) (29.2 — 35.7) (0.4 — 5.3)
pb NSC NS <0.001 <0.01 NS <0.05
a Values given are mean I SD and numbers in parenthesis indicate range of the parameter measured
b Values compare No androgen and Androgen populations
Indicates differences were not statistically significant
Table 2. Blood gas measurements and acid base status of CHD patients
Serum Arterial Arterial Hgb-02
HCO3t Arterial PO2 pCO2 saturation
pHMa mEqiliter pH (torr) torr %
No androgens (13) 7.29 0.05 (t5)C 20.02 5 (15) 7.39 0.07 84 Ii 35.7 3.4 96.1 l.9
(7.19 — 7.38) (16.0 — 24.0) (7.30 — 7.56) (68 — 102) (29 — 41) (91.8 — 97.8)
Androgens (12) 7.28 0.09 (17) 19.7 9.6 (17) 7.38 0.04 77 14 33.7 7.1 94.8 3.1
(7.09 — 7.40) (13.0 — 25.0) (7.26 — 7.43) (51 — 107) (22 — 41) (89.2 — 97.6)P NS' NS NS NS NS NS
a Value in 13 normal subjects is 7.43 0.04; P < 0.001 vs. both NA and A groups
b Value in 13 normal subjects is 27.0 2.4; P < 0.001 vs. both NA and A groups
Values given are mean I SD and numbers in parenthesis indicate the range of the parameter measuredd Indicates differences were not statistically significant
(P5074) and to the measured arterial pH using the slopes of the
regression lines generated from plots of PHM vs. log PSOM.
Since all subjects were euthermic, no additional correction was
made for body temperature. Arterial Hgb-02 saturation in vivo
was determined from the measured arterial P°2 and the calcu-
lated arterial P50 following correction for base excess using the
Severinghaus slide rule [241. Simultaneous ATP and DPG levels
were determined immediately on trichioroacetic acid extracts of
freshly drawn venous blood using enzymatic methods [25, 26].
The statistical significance of differences in the laboratory
findings in the patient groups studied were determined by
means of two—sided t-distribution and chi—square analyses [27].
Regression analyses and F-distribution analyses were per-
formed as described by Snedecor and Cochran [28]. Stepwise
multiple regression analyses were performed using a BMO
biomedical computer program [29].
Subjects
Fifteen normal hospital personnel and 32 male patients on
hemodialysis for at least four months for end—stage renal
disease were studied. The hemodialysis program for all patients
included thrice weekly dialyses using a Gambro GLP 11.5
dialyzer; vitamin supplements containing 1.0 mg/day of folic
acid and iron in the form of monthly intravenous injections of
iron dextran (Imferon®). The dose of iron dextran was adjusted
to maintain adequate total body iron stores as determined by
serum ferritin determinations. At the time of study, serum
ferritin levels were greater than 50 ng/ml in all but two subjects,
one in each of the CHD groups. This program has been
essentially unchanged for the last eight years. Fifteen of these
patients received no additional hematinic agents and were
designated as the No Androgen (NA) group. The remaining 17
patients, designated as the Androgen (A) group, had been
receiving androgens intramuscularly in the form of nandrolone
decanoate (DD) 100 mg/week (five patients) or testosterone
cypionate (DT) 200 mg/week (12 patients) for periods of 39 to 59
months. The equivalent effects of these two agents on hemo-
globin levels in this population have previously been reported
[91. None of the patients in either CHD group had received
blood transfusions for at least four months prior to study. As
shown in Table 1, NA and A subjects did not differ significantly
in age, BUN or creatinine levels, but A patients had been on
hemodialysis longer (70.2 24.8 months) than the NA group
(11.3 7.4 months; P <0.001). Preandrogen mean Hgb in the
A group (8.26 1.41 g/dl) was almost identical to that of the NA
group (Table 1). The mean Hgb in 13 of the NA patients in
whom follow—up was available after the present study remained
unchanged (8.34 1.16 g/dl) five to 49 months later, but
increased to 11.37 2.75 g/dl within one year after beginning
androgen therapy.
Results
Determinants of hemoglobin levels
Both CHD populations had significantly lower Hgb levels (P
<0.001) and MCHC values (P < 0.002) than normal subjects
(Table 1). However, Hgb levels in A patients were almost 50%
higher than in NA subjects. This could not be explained by
differences in arterial P°2 or Hgb-02 saturations. (Table 2).
Reticulocyte indices and MCV values were also significantly
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Table 3. Red cell phosphate metabolism and hemoglobin—oxygen affinity
Serum
phosphate
mg/dl
ATP
smol/g Hgb
DPG
molIg Hgb torT
!L1
torr
Hill
coefficient
Normal (15) 2.8 O.5c
(2.0 — 3.3)
4.88 0.44
(4.03 — 5.55)
13.64 1.81
(10.96 — 15.63)
26.7 1.2
(24.0 — 28.0)
27.9 1.6 (12)
(25.2 — 31.0)
2.67 0.10
(2.51 — 2.80)
No androgens 5.1 0.9
(3.7 — 6.7)
7.75 1.00
(5.66 9.10)
15.54 4.67
(7.90 — 22.21)
29.8 3.1
(24.8 — 35.5)
26.4 2.5
(22.5 — 31.3)
2.68 0.11
(2.49 — 2.88)P <0.001 <0.001 NS' <0.005 NS NS
Androgens (17) 5.0 1.7
(3.6 — 9.9)
6.83 1.08
(5.25 — 8.80)
17.35 3.84
(9.90 — 25.10)
29.4 2.4
(26.5 — 33.0)
27.6 1.9
(24.7 — 30.8)
2.74 0.24
(2.39 — 3.39)P <0.001 <0.001 <0.005 <0.005 NS NS
pb NS <0.02 NS NS NS NS
a Compares normal subjects with either NA or A dialysis groups
b Compares NA patients with the A group
Values given are means 1 SD and numbers in parentheses indicate the range of the parameter measured
'Of 15 NA patients, 7 had RBC DPG > 16 jirnol/g Hgb (i.e. more than 1 SD greater than the normal mean), = 4.779; P = 0.029
greater in the A population (Table 1). Hgb levels in A subjects
did not correlate with time on dialysis (r = 0.20). However, a
direct correlation was noted between Hgb levels and reticulo-
cyte indices in this population (r = 0.57; P < 0.02). Relation-
ships between Hgb levels and either serum phosphate (NA, r =
—0.10; A, r = 0.19) or arterial Hgb-oxygen saturation (NA, r =
0.09; A, r = 0.01) were not significant.
Determinant of red cell organic phosphate levels
Both CHD groups had higher RBC ATP and DPG levels than
normal subjects (Table 3). An inverse correlation between DPG
levels and Hgb was observed in normal subjects (r =
—0.55; P
<0.05) but was not present in either CHD group (NA, r =0.17;
A, r 0.38). RBC DPG levels were not significantly related to
time on dialysis (NA, r =
—0.20; A, r = 0.10); to the level of the
reticulocyte count (NA, r = 0.35; A, r = 0.13); orto the arterial
Hgb-02 saturation (NA, r =
—0.41; A, r = 0.08) in either CHD
population.
Serum phosphate levels were increased to the same degree in
both NA and A patients and a direct relationship of RBC DPG
to serum phosphate was suggested in both CHD populations
(Fig. 1). However, there were distinct differences in RBC
organic phosphates between the two dialysis groups. ATP
levels were significantly lower in A subjects than in NA patients
(Table 3) and an inverse correlation between ATP and Hgb was
noted in the A population (Fig. 2). In addition, RBC DPG was
higher in A than in NA patients, but this difference was not
statistically significant (Table 3).
Determinants of hemoglobin—oxygen affinity (P50)
The Hill coefficient was similar in normal subjects and both
CHD populations (Table 3). However, CHD patients had sig-
nificantly lower Hgb-oxygen affinity (higher PSOM values) than
normal subjects. P5051 values were not significantly correlated
with Hgb levels (NA, r = 0.10; A, r = 0.23), reticulocyte counts
(NA, r = 0.36; A, r = 0.28), arterial Hgb-02 saturations (NA, r
= 0.35; A, r = 0.16), or time on dialysis (NA, r = —0.20; A, r
= 0.04).
P5051 values were similar in A and NA subjects. As ex-
pected, both CHD populations had lower serum bicarbonate
levels and correspondingly lower PHM values than normal
subjects (Table 2). However, analysis of the determinants of
Hgb-02 affinity suggested differences in the two dialysis groups
(Table 4). In NA subjects, PSOM was directly related to RBC
DPG and serum phosphate, and inversely related to MCHC and
pHM. In contrast, in A subjects only the relationship between
pHM and PSOM was statistically significant. The difference in
the relationship of serum phosphate to PSOM in NA and A
patients was statistically significant (F for slopes = 5.612; P
0.025), while the difference in the relationship of DPG to P5OM
in the two CHD groups approached statistical significance (F =
2.6064; P = 0.09).
Moreover, while the relationship between pHM and PSOM
was significant in both CHD groups, an effect of androgen
therapy on the response of Hgb-oxygen affinity to changes in
pH was also suggested. In NA subjects, the slope of the
regression line for PHM versus P5051 (that is, the Bohr coeffi-
cient) was similar to that previously described in normal sub-
jects and in patients with a variety of acid—base disorders (Fig.
3) [30]. Although not statistically significant, a lower slope was
noted in the A population (F for slopes = 1.860; P = 0.18).
No androgen
DPG = 2.47 Pi + 2.89
r=0.46; P=0.08
Androgen
DPG = 1.35 P1 + 9.83
r= 0.60; P<0.02 .
r)
20-0
E
16-
12-
c'l
8-
S •
.0
.
.
10
Serum phosphate, mg/dI
Fig. 1. Effect of serum phosphate on red cell DPG in different chronic
hemodialysis populations. Hatched boxes represent mean values I SD
for 15 normal subjects. Symbols are: (0) NA patients; (•) A patients on
testosterone cypionate; () A patients on nandrolone decanoate.
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Hgb, g/dI
Fig. 2. Relationship between red cell ATP content and hemoglobin
levels in androgen.-.treated chronic hemodialysis patients. Symbols are
as defined in Figure 1.
Table 4. Determinants of hemoglobin—oxygen affinity in chronic
hemodialysis patients
No androgens Androgens
PSOM P5074 P5OM P5074
Correlation coefficients
DPG
MCHC
Phosphate
PHM
084b
0.69"
o59a 0.48
—0.48 —0.28
0.69" 0.48
—
—0.58'
0.11
—0.22
0.16
When P50 values were corrected to a pH 7.4, Hgb-oxygen
affinity in NA and A subjects did not differ from those in the
normal population, confirming previous reports (Table 3) [31,
32]. Significant direct correlations between P5074 and both
DPG and serum phosphate were again present in NA subjects
but not in the A group (Table 4). A stepwise regression analysis
was performed to determine the relative contributions of DPG,
pHM, MCHC, and serum phosphate to PSOM in the two CHD
populations. As shown in Table 5, DPG explained 70% of the
variance in 5OM in NA subjects and only 2% in A subjects. In
contrast, pHM accounted for 34% of the variance of PSOM in the
A group, but was not a significant independent variable in the
NA population.
Thus, an effect of androgen therapy on the RBC milieu which
modifies the determinants of oxygen affinity was suggested.
This was further supported by observations on the relationship
between PHM and MCHC. Increasing pH was associated with
increasing MCHC values in the NA population and in normal
subjects. However, this relationship was not significant in the A
group (Fig. 4).
1.35-
7.20 7.30 7.10 7.20 7.30 7.40
pHM pHM
Fig. 3. Effect of pH on hemoglobin—oxygen affinity in chronic hemodi-
alysis populations. The log of hemoglobin-oxygen affinity (P5OM) was
correlated with pH in chronic hemodialysis patients not receiving
androgen therapy (0) and in chronic hemodialysis patients receiving
either testosterone cypionate or nandrolone decanoate (•, •). The
Bohr coefficient is defined as the slope of the resulting regression line.
Table 5. Stepwise multiple regression analysis of hemoglobin-oxygen
affinity determinants
Dependent
variable
Independent
variables
No Androgens Androgens
r2
PSOM DPG
Phosphate
MCHC
PHM
0.70
0.12
0.03
<0.01
0.02
0.05
0.03
0.34
7.20 7.30 7.40 7.50 7.10 7.20 7.30 7.40
pHM PHM
Fig. 4. Effect of pH on MCHC in normal and chronic hemodialysis
populations. MCHC was correlated with pH in normal subjects (A);
chronic hemodialysis patients not receiving androgen therapy (0); and
chronic hemodialysis patients receiving either testosterone cypionate(•) or nandrolone decanoate (•).
Effects of different androgens
Treatment with DD and DT had similar effects on erythro-
poiesis, RBC metabolism and hemoglobin—oxygen affinity (Ta-
ble 6). Moreover, correlations between variables in patients
treated with DT (the larger subset), were similar to those noted
in the entire population. Thus, in DT subjects, Hgb was directly
related to the reticulocyte index (r = 0.65;P < 0.025); ATP was
inversely related to Hgb (r =
—0.67; P < 0.02); DPG was
0
:1.
a-I-4
.
.
.
101 AridrogensATP=
—0.21 Hgb+9.34
r=
—0.52; P<0.05
No androgens
Log P5OM= —0.46 pH+4.849
r=
—0.59; P<0.025
Androgens
Log P50M —0.22 pH+3.067
r= —0.58; P<0.02
•
1.60
1.551
o 1.501
Li) IQ.
° 1.45o
a
o°o
1.601
1.55
1.45
l.4O .. 1.40-
9-
8-
7-
6-
5-
.
.
.
.
.
••
10 12 14 16
a P < 0.025
b p < 0.005
No androgen + Normal
MCHC= 13.7 pHM + 67.7
r=0.60; P<0.005
39
I33>t
29 F slopes=3.926
27 P=0.05
Androgens
MCHC= 2.21 pHM+ 15.8
r=0.13; NS
39
37
35
33 *
31
29
27
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Table 6. Effects on different androgens on hematopoiesis and red cell metabolism
Hemoglobin
gidI
Reticulocyte
index
%
MCH
gidi
C ATP
p.mol/g Hgb
DPG
mol/g Hgb
PSOM
rorr
Testosterone cypionate (12)
Nandrolone decanoate (5)
P
11.05
11.92
NS
2.64a
2.21
2.0 1.4
1.8 1.9
NS
31.6
32.5
NS
1.5
1.9
6.87 1.12
6.73 1.08
NS
17.15 4.02
17.85 3.74
NS
29.2 2.5
29.9 2.1
NS
a Values are mean I SD
directly related to serum phosphate (r 0.88; P < 0.001) and
P5OM was inversely related to PHM (r —0.65; P < 0.025), but
not to MCHC (r = —0.33). Finally, while PSOM was directly
related to DPG in DT patients (r = 0.60; P < 0.05), DPG was
not a significant determinant of hemoglobin—oxygen affinity
when P50 values were corrected to pH 7.4 (r = 0.10).
Discussion
Previous studies have documented increased RBC levels of
ATP and DPG in CHD subjects [33—39]. These changes have
been variably correlated with the presence of a younger RBC
population in the peripheral blood and/or with increased RBC
glycolytic rates associated with hyperphosphatemia [34, 36—38].
Similarly, in the present study, RBC ATP and DPG levels were
increased in both CHD populations and DPG levels were
positively correlated with the serum phosphate (Table 3, Fig.
1). DPG levels were inversely related to Hgb level in the normal
subjects studied, but no correlation was noted between RBC
DPG and the severity of anemia in either NA or A subjects.
While inverse relationships between Hgb levels and RBC DPG
have previously been reported in many anemic states as well as
in normal subjects [40, 41], a lack of such correlation has also
been noted by other investigators in some anemic populations
including CHD patients [31, 42—45]. Moreover, DPG did not
correlate with arterial Hgb-02 saturation in either CHD group.
Thus, metabolic factors appear to be stronger determinants of
RBC DPG levels in the CHD setting than either the severity of
anemia or hypoxia.
Androgen therapy was associated with additional alterations
in RBC organic phosphate levels in CHD subjects. In the A
population, RBC ATP levels were significantly lower and DPG
levels somewhat higher than in the NA group (Table 3).
Moreover, RBC ATP in the A group was inversely related to
the level of hemoglobin in these subjects (Fig. 2). While RBC
DPG has been noted to increase during androgen therapy
[16—18], long—term effects on RBC ATP have not been previ-
ously studied. These changes in RBC metabolic intermediates
can result from: 1) the production of a RBC population of
younger median age during androgen therapy; and/or 2) a direct
effect of androgens on RBC metabolism. The presence of
younger circulating RBC in A subjects is supported by the
finding of higher reticulocyte counts in these patients (Table 1).
Indeed, DPG levels have been found to be higher in reticulo-
cytes than in older, more mature RBC [46—481. However, RBC
ATP is also increased in younger RBC populations in normal
subjects, CHD subjects and patients with hemolytic anemias
[48, 49]. Thus, decreased RBC age and reticulocytosis would be
expected to increase both DPG and ATP levels. The combina-
tion of lower ATP and higher DPG levels observed in A
subjects, therefore, suggests a direct effect of androgens on
RBC metabolism. Indeed, in vitro studies have also shown that
hormones or their metabolites can modify metabolism in circu-
lating RBC. Thus, extracts of plasma from testosterone—treated
rats stimulate glycolysis and increase RBC DPG in reticulo-
cytes from untreated litter—mates [18]. Similarly, thyroid hor-
mone increases RBC DPG levels in vitro, most likely by
stimulating the diphosphoglycerate mutase enzyme [50].
In addition, analysis of the determinants of Hgb-oxygen
affinity suggested an effect of androgens on the red cell milieu.
Although Hgb-oxygen affinity was decreased to the same de-
gree in both CHD groups, DPG accounted for 70% of the
variance of 50M in NA subjects, but less than 2% in A
subjects. Thus, while DPG was still an important determinant of
Hgb-02 affinity when P50 values were adjusted to pH 7.4 in NA
patients, this was not the case in the A population. Similarly,
serum phosphate was a significant determinant of both PSOM
and P5074 in NA subjects, but not in the A group (Table 4).
Furthermore, while PHM was a significant determinant of P5OM
in both CHD groups, it was of note that the Bohr coefficient was
lower in A patients than in the NA population (Fig. 3). Finally,
while fully 85% of the variance in 5OM is explained by the
variables studied in NA subjects, these variables explain only
44% of the variance of 5OM in the A group (Table 5). Thus, in
the A group, other major factors impacting on Hgb-02 affinity
remain undefined, and even the overall impact of pH is rela-
tively small (that is, 34% of the variance of PSOM).
Taken together, these findings suggest that while net P50 and
DPG levels are not significantly altered in the A population, the
adaptability of RBC oxygen transport to changes in both
systemic pH and systemic oxygen supply and demand may be
limited during androgen therapy. Since androgens increase the
basal metabolic rate (and thus oxygen demand as well) as much
as 15% in man [51], these changes may decrease the potential
clinical benefit to be derived from androgen—stimulated
erythropoiesis. Indeed, in the ambient state, administration of
nandrolone decanoate to mice acutely increases serum eryth-
ropoietin, RBC DPG and P50 values. However, hyperoxia
blocks the erythropoietin response to androgen therapy but
does not prevent the increase in DPG and P50 seen in these
animals [52]. Thus, a negative effect of androgens on net tissue
oxygen supply is suggested.
The benefit of androgen therapy in the anemia of chronic
renal disease will depend on the net effect of androgens on
oxygen transport resulting from changes in: 1) the red cell mass;
2) tissue oxygen utilization; and 3) hemoglobin—oxygen binding
characteristics (Fig, 5). Many studies have documented an
increase in red cell mass during androgen therapy in CHD
patients [1—9]. On the other hand, consideration of the anabolic
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Fig. 5. Possible effects of androgens on oxygen transport and metabo-
lism.
effect of androgens has led to speculation that tissue oxygen
requirements may also be increased [16, 17]. This possibility
has not been directly studied. However, in contrast to cobalt,
androgens do not appear to impair tissue oxygen uptake [53].
Five studies have looked at factors affecting Hgb-oxygen trans-
port during androgen therapy [16—18, 54, 55]. In rodents and
monkeys with normal renal function, androgens increase RBC
DPG [16, 18] and this is associated with an increase in P50
values [16]. The latter change would be expected to improve
tissue oxygen delivery. Similarly, in CHD patients, RBC DPG
levels significantly increased during treatment with 400 to 600
mg per week of testosterone enanthate [17] and in normal
subjects, DPG increased 24 to 48 hours after a single 50 mg dose
of oxymetholone [54]. The authors of the former study postu-
lated that this would also decrease Hgb-oxygen affinity, but
P50 values were not actually determined. No previous studies
have looked at the effects of androgens on heme—heme interac-
tions, which can also markedly alter tissue oxygen delivery
from RBC [56]. In contrast, in the present study, perhaps as a
result of the lower doses of androgens used, only a modest
increase in RBC DPG was seen and no effect on Hgb-oxygen
affinity (P50) or heme—heme interaction (Hill coefficient) was
noted (Table 3). Goodman and Bessman also failed to note
increases in RBC DPG in nine CHD patients treated with 200
mg per week of nandrolone decanoate [55]. Since DPG has very
little impact on P50 values in A patients (Table 5), the use of
other androgen regimens to produce greater increments in DPG
may not further improve oxygen delivery in the CHD popula-
tion.
Our findings suggest that androgen therapy modifies the
interaction of Hgb with DPG, phosphate—related processes and
hydrogen ions within the mature RBC, The mechanisms which
might produce these changes remain undefined. It is of note that
urea—derived cyanate can lead to carbamylation of Hgb in
uremic subjects [57]. Thus, androgens may enhance or diminish
the modification of Hgb by cyanate or other uremic toxins.
Alternatively, androgens may modify the properties of Hgb by
mediating a change in the intracellular ionic composition. This
is supported by the change in relationship between pH and
MCHC noted in androgen—treated patients (Fig. 4) [58]. Finally,
androgens may directly affect the entire metabolic makeup of
the RBC by altering protein synthesis on RBC progenitors
and/or protein function in mature RBC. Our preliminary studies
of RBC enzyme activities in these subjects indeed suggest that
this may be the case [59].
Acknowledgments
This study was supported in part by a grant from the Veterans
Administration. We would like to thank Carol Broshjeit and Helen Kern
for performing laboratory studies, Walter Sudol for manuscript prepa-
ration and Emanuel Lerner for statistical assistance.
Reprint requests to Dr. ED. Hendler, Veterans Administration
Medical Center, West Spring Street, West Haven, Connecticut 06516,
USA
References
1. DEGOWIN RL, LAVENDER AR, FORLAND M, CHARLESTON D,
GOTTSCHALK A: Erythropoiesis and erythropoietin in patients with
chronic renal failure treated with hemodialysis and testosterone.
Ann mt Med 72:913—918, 1970
2. RICHARDSON JR, WEINSTEIN MB: Erythropoietic response of
dialyzed patients to testosterone administration. Ann Jut Med 73:
403—407, 1970
3. ESCHBACH JW, ADAMSON JW: Improvement in the anemia of
chronic renal failure with fluoxymesterone. Ann Jut Med 78:527—
532, 1973
4. FRIED W, JONASSON 0, LANG F, SCHWARTZ F: The hematologic
effect of androgen in uremic patients. Ann mt Med 79:823—827, 1973
5. WILLIAMS JS, STEIN JG, FERRIS TF: Nandrolone deconate therapy
for patients receiving hemodialysis. Arch Jut Med 134:289—292,
1974
6. HENDLER ED, GOFFINET JA, Ross S, LONGNECKER RE, BAKOVIC
V: Controlled study of androgen therapy in anemia of patients on
maintenance hemodialysis. N EnglJ Med 291:1046—1051, 1974
7. BUCHWALD D, ARGYRE5 S, EASTERLING RE, OELSHLEGEL FJ,
BREWER GJ, SCHOOMAKER EB, ABBRECHT PH, WILLIAMS GW,
WELLER JM: Effect of nandrolone decanoate on the anemia of
chronic hemodialysis patients. Nephron 18:232—238, 1977
8. CATTRAN DC, FENTON SSA, WILsoN DR, OREOPOULOS D,
SHIMIZU A, RICHARDSON RM: A controlled trial of nandrolone
decanoate in the treatment of ureniic anemia. Kidney Jut 12:
430—437, 1977
9. NEFF MA, GOLDBERG J, SLIFKIN RF, EISER AR, CALAMIA V,
KAPLAN M, BAEZ A, GUPTA 5, MATTOO N: A comparison of
androgens for anemia in patients on hemodialysis. N EngI J Med
304:871—875, 1981
10. GORDON AS, ZANJANI ED, LEVERE RD, KAPPAS A: Stimulation of
mammalian erythropoiesis by 513 steroid metabolites. Proc Natl
Acad Sci 65:919—924, 1970
11. GORSHEIN D, HAlT WN, BESA EC, JEPSON JH, GARDNER FH:
Increased stem cell response to erythropoietin induced by andro-
gens. Endocrinol 93:777—780, 1973
12. GORSHEIN D, HAlT WN, BESA EC, JEPSON JH, GARDNER FH:
Rapid stem cell differentiation induced by 19-nortestosterone deca-
noate. Br J Hacmatol 26:215—225, 1974
13. PESCHLE C, BARBA P, CILLO C, MAGLI MC, MIGLIACCIO G,
PIZZELLA F, RAPPAPORT IA: Testosterone action on BFU-E and
CFU-E: Correlation between enhancement of proliferative rate and
amplification of pool size. Life Sci 24:1165—1172, 1979
14. PAULO LG, FINK GD, ROLF BL, FISCHER JW: Effects of several
androgens and steroid metabolites on erythropoietin production in
the isolated perfused dog kidney. Blood 43:39—47, 1974
15. MODDER B, FOLEY JE, FISHER JW: The in vitro and in vivo effects
of testosterone and steroid metabolites on erythroid colony forming
cells (CFU-E). J Pharmacol Exp Ther 207:1004—1012, 1978
16. GORSHEIN D, OsKI FA, DELIVORIA—PAPADOPOULOS: Effect of
androgens on the red cell 2,3-diphosphoglycerate, hemoglobin
oxygen affinity and red cell mass in mammals. Proc Soc Exp Biol
Med 147:616—618, 1974
17. PARKER JP, BEIRNE GJ, DESAI JN, RAICH PC, SHAHIDI NT:
Androgen—induced increase in red cell 2,3-diphosphoglycerate. N
,,1V'[
ABC
_________
mass
A
n
d
0
g
e
ii
106 Hendler and Solomon
Eng J Med 287:381—383, 1972
18. M0LINARI PF, CHUNG SK, SNYDERLM: Variations of erythrocyte
glycolysis following androgens. J Lab Clin Med 81:443—446, 1973
19. VANKAMPEN EJ, ZIJLSTRA WF: Standardization of hemoglobinom-
etry: II. The hemoglobin—cyanide method. (abstract) Clin Chim
Ada 6:538, 1961
20. HILLMAN RS, FINCH CA: The Red Cell Manual, Philadelphia, F.A.
Davis Co., 1974, p. 60
21. MILES LE, LII'SCHITZ DA, BILBER CP, CooK JD: Measurement of
serum ferritin by a two—site immunoradiometric assay. Analyt
Biochem 61:209—224, 1974
22. GOKAL R, MILLARD PR, WEATHERALL DJ, CALLENDER STE,
LEDINOHAM JUG, OLIVER DO: Iron metabolism in hemodialysis
patients. QJMed 191:369—391, 1979
23. NEVILLE JR: Hemoglobin oxygen affinity measurement using bio-
tonometry. J AppI Physiol 37:967—971, 1974
24. SEVERINGHAUS JW: Blood gas calculator. J Appi Physiol 21:
1108—1116, 1966
25. ADAMS H: Adenosine 5-triphosphate; determination with phospho-
glycerate kinase, in Methods of Enzymatic Analyses, edited by
BURGMEYER HU. New York, Academic Press, 1963, p. 539
26. Sigma Technical Bulletin No. 35-UV. St. Louis, 1974
27. HILL AB: Principles of Medical Statistics, (9th ed). New York,
Oxford University Press, 1971, pp. 131—179
28. SNEDECOR G, COCHRAN W: Statistical Methods, (6th ed). Ames,
Iowa State University Press, 1973, p. 135
29. DIxoN WJ: BMO Biomedical computer programs-P Series. Los
Angeles, University of California Press, 1979
30. WRANNE B, WooDsoN RD, DETTER JC: Bohr effect: Interaction
between H+, CO2 and 2,3-DPG in fresh and stored blood. J App!
Physiol 32:749—754, 1972
31. LICHTMAN MA, MURPHY MS. WHITBECK AA, KERANEY GA:
Oxygen binding to hemoglobin in subjects with hypoproliferative
anemia with and without chronic renal disease: Role of pH. Br J
Haemat 27:439—451, 1974
32. MITCHELL TR, PEGRUM GD: The oxygen affinity of haemoglobin in
chronic renal failure. Br J Haematol 21:463-472, 1971
33. HUNT GA, CHANUTIN A: Organic phosphate compounds of eryth-
rocytes from individuals with uremia. J Lab Clin Med 64:675—684,
1964
34. LICHTMAN MA, MILLER DR: Erythrocyte glycolysis, 2,3-diphos-
phoglycerate and adenosine triphosphate concentration in uremic
subjects: Relationship to extracellular phosphate concentration. J
Lab Clin Med 76:267—279, 1970
35. BLUMBERG A, SCHERRER M, MARTI HR. MEYER M: Red Cell
organic phosphate levels and in vivo oxygen—hemoglobin dissocia-
tion in patients on maintenance hemodialysis with anemia. Blut
22:109—115, 1971
36. BLUMBERO A, MARTI HR: Adaptation to anemia by decreased
oxygen affinity of hemoglobin in patients on dialysis. Kidney ml
1:263—270, 1972
37. WALLAS CH: Metabolic studies on the erythrocyte from patients
with chronic renal disease on hemodialysis. II. ATP metabolism. Br
J Haematol 27:145—152, 1974
38. LICHTMAN MA, MURPHY MS, BYER, FREEMAN RB: Hemoglobin
affinity for oxygen in chronic renal disease. The effect of hemodi-
alysis. Blood 43:417—424, 1974
39. CHILLAR R, DESFORGE5 J: Red cell organic phosphates in patients
with chronic renal failure on maintenance hemodialysis. Br J
Haematol 26:549—556, 1974
40. BREWER GJ, EATON JW: Erythrocyte metabolism: Interaction with
oxygen transport. Science 171:1205—1211, 1971
41. HJELM M: The content of 2,3-diphosphoglycerate and other phos-
phocompounds in human erythrocytes from healthy adults and
subjects with different types of anemia. Forsvarsmedicin 5:219—
227, 1969
42. TORRANCE J, JACOBS P, RESTREPO A, E5CHBACH J, LENFANT C,
FINCH CA: Intraerythrocytic adaptation to anemia. N Eng J Med
283:165—169, 1970
43. POLLOCK A, COTTER KP: Oxygen transport in anemia. Br J
Haematol 25:631—636, 1973
44. SLAWsKY P, DE5FORGES JF: Erythrocyte 2,3-diphosphoglyCerate
in iron deficiency. Arch Inter Med 129:914—917, 1972
45. ASTRUP P, RORTH M, THORSHAUGE C: Dependency of acid—base
status of oxyhemoglobin dissociation and 2,3-diphosphoglycerate
level in human erythrocytes: In vivo studies. Scand J Clin Lab
Invest 26:47—52, 1970
46. BUNN HF, MAY MH, KOCHOLATY WF, SHIELDS CE: Hemoglobin
function in stored blood. J Clin Invest 48:311—321, 1969
47. HAIDAS 5, LABIE D, KAPLAN JC: 2,3-diphosphoglycerate content
and oxygen affinity as a function of red cell age in normal individ-
uals. Blood 38:463—467, 1971
48. WU AF, WU TT: Concentrations of glucose-6-phosphate dehydrog-
enase, adenosine triphosphate and 2,3-diphosphoglycerate in nor-
mal erythrocytes fractionated by velocity sedimentation. (abstract)
Fed Proc 39:1037, 1980
49. LICTHMAN MA, MURPHY MS: Red Cell adenosine triphosphate in
hypoproliferative anemia with and without chronic renal disease:
Relationship to hemoglobin deficit and plasma inorganic phosphate.
Blood Cells 1:467-484, 1975
50. SNYDER LM, REDDY WJ, KURIJAN L: Mechanisms of action of
thyroid hormones on erythrocyte 2 ,3-diphosphoglyceric acid syn-
thesis. J Clin Invest 49: 1933—1938, 1970
51. GUYTON AC: Textbook of Medical Physiology (6th ed). Philadel-
phia, W.B. Saunders Co., 1981, pp. 999—1000
52. GORSHEIN D, GARDNER FH, TYREE W, OSKI F, DELIVORIA—PAPA-
DOPOULOS: Effects of hyperoxia and androgen on red cell 2,3-
diphosphoglycerate and oxygen affinity. Acta Haemat 55:306—312,
1976
53. THORLING EB, ERSLEY AJ: The effect of some erythropoietic
agents on tissue tension oxygen. Br J Haematol 23:483—490, 1972
54. MOLINARI PF, LERI LL: Effect of a single dose of oxymetholone on
the metabolism of human erythrocytes. Exp Hemat 6:648—654, 1978
55. GOODMAN J, BESSMAN AN: Effect of nortestosterone decanoate on
red cell 2,3-diphosphoglycerate and hematocrit in hemodialysis
patients. Clin Pharmacol Ther 17:167—170, 1975
56. NEVILE JR: Altered haem—haem interaction and tissue—oxygen
supply. A theoretical analysis. Br J Haematol 35:387—395, 1977
57. FLUCKIGEN R, HARMON W, MERER, W, Loo S, GABBAY KB:
Hemoglobin carbamylation in uremia. N Eng J Med 304:823—827,
1981
58. BELLINGHAM AJ, DETTER JC, LEFANT C: Regulatory mechanisms
of hemoglobin oxygen affinity in acidosis and alkalosis. J Clin
Invest 50:700—706, 1971
59. SOLOMON L, HENDLER E: Androgen therapy in hemodialysis
patients: II. Effects on red cell metabolism. Br J Haematol (in
press)
